A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TOP1288 Oral Single Ascending and Multiple Doses in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs TOP 1288 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors TopiVert
- 06 Jul 2017 Status changed from recruiting to completed.
- 28 Feb 2017 Status changed to recruiting.
- 06 Oct 2016 Results from this trial are expected in the second half of 2017, according to a TopiVert media release.